A Review of Nebivolol Pharmacology and Clinical Evidence.
Drugs
; 75(12): 1349-71, 2015 Aug.
Article
em En
| MEDLINE
| ID: mdl-26177892
ABSTRACT
Nebivolol is a highly selective ß1-adrenergic receptor antagonist with a pharmacologic profile that differs from those of other drugs in its class. In addition to cardioselectivity mediated via ß1 receptor blockade, nebivolol induces nitric oxide-mediated vasodilation by stimulating endothelial nitric oxide synthase via ß3 agonism. This vasodilatory mechanism is distinct from those of other vasodilatory ß-blockers (carvedilol, labetalol), which are mediated via α-adrenergic receptor blockade. Nebivolol is approved for the treatment of hypertension in the US, and for hypertension and heart failure in Europe. While ß-blockers are not recommended within the current US guidelines as first-line therapy for treatment of essential hypertension, nebivolol has shown comparable efficacy to currently recommended therapies in lowering peripheral blood pressure in adults with hypertension with a very low rate of side effects. Nebivolol also has beneficial effects on central blood pressure compared with other ß-blockers. Clinical data also suggest that nebivolol may be useful in patients who have experienced erectile dysfunction while on other ß-blockers. Here we review the pharmacological profile of nebivolol, the clinical evidence supporting its use in hypertension as monotherapy, add-on, and combination therapy, and the data demonstrating its positive effects on heart failure and endothelial dysfunction.
Texto completo:
1
Temas:
ECOS
/
Aspectos_gerais
Bases de dados:
MEDLINE
Assunto principal:
Vasodilatadores
/
Agonistas de Receptores Adrenérgicos beta 1
/
Nebivolol
/
Insuficiência Cardíaca
/
Hipertensão
/
Anti-Hipertensivos
Tipo de estudo:
Diagnostic_studies
/
Guideline
Limite:
Animals
/
Humans
Idioma:
En
Revista:
Drugs
Ano de publicação:
2015
Tipo de documento:
Article
País de afiliação:
Estados Unidos